Sara Fresnillo Saló

Ms. Sara Fresnillo Saló

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
KFKlaire Yixin Fjæstad
Klaire Yixin Fjæstad
AJAstrid Zedlitz Johansen
Astrid Zedlitz Johansen
HLHannes Linder
Hannes Linder
KBKevin James Baker
Kevin James Baker
MSMilou Schattefor
Milou Schattefor
DMDaniel Hargbøl Madsen
Daniel Hargbøl Madsen
β-adrenergic signaling has been suggested to promote tumor growth, and β-blockers are being evaluated for repurposing for cancer treatment. Here, we identify a β-adrenergic signaling axis involved in metastasis formation. We show that the β-blocker propranolol has strong anti-metastatic activity in multiple murine models, with this effect being completely dependent on CD4 + T cells and independent of NK or CD8 + T cells. We also observe that CD4 + T cells are required for the anti-tumor effect of propranolol in a syngeneic subcutaneous model of colon cancer. Mechanistically, propranolol induces a Th1-polarized and cytotoxic CD4 + T cell response, which requires MHC class II expression by cancer cells for full efficacy. We also report propanolol-driven systemic changes in the monocyte compartment, and upon depletion of monocytes, propranolol loses its anti-tumor effects. Finally, we show that propranolol treatment synergizes with anti-CTLA-4 therapy to further enhance CD4 + T cell infiltration and control metastasis. Thus, we show that β-adrenergic signaling limits CD4 T cell-mediated anti-tumor immunity, highlighting the potential of repurposing β-blockers for cancer treatment.

1 May 2024 in Cytotherapy
Verified
Journal Article
Open access
PAPia Aehnlich
Pia Aehnlich
MSMarta Velasco Santiago
Marta Velasco Santiago
SDSøren Helweg Dam
Søren Helweg Dam
SSSara Fresnillo Saló
Sara Fresnillo Saló
ARAnne Rahbech
Anne Rahbech
GOGitte Holmen Olofsson
Gitte Holmen Olofsson
Background aims: Vy9VS2 T cells are under investigation as alternative effector cells for adoptive cell therapy (ACT) in cancer. Despite promising in vitro results, anti-tumor efficacies in early clinical studies have been lower than expected, which could be ascribed to the complex interplay of tumor and immune cell metabolism competing for the same nutrients in the tumor microenvironment. Methods: To contribute to the scarce knowledge regarding gamma delta T-cell metabolism, we investigated the metabolic phenotype of 25-day-expanded Vy9VS2 T cells and how it is intertwined with functionality. Results: We found that Vy9VS2 T cells displayed a quiescent metabolism, utilizing both glycolysis and oxidative phosphorylation (OXPHOS) for energy production, as measured in Seahorse assays. Upon T-cell receptor activation, both pathways were upregulated, and inhibition with metabolic inhibitors showed that Vy9VS2 T cells were dependent on glycolysis and the pentose phosphate pathway for proliferation. The dependency on glucose for proliferation was confirmed in glucose-free conditions. Cytotoxicity against malignant melanoma was reduced by glycolysis inhibition but not OXPHOS inhibition. Conclusions: These findings lay the groundwork for further studies on manipulation of Vy9VS2 T-cell metabolism for improved ACT outcome. (c) 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

13 July 2025 in OncoImmunology
Verified
Journal Article
Open access
AKAnnina Kurzay
Annina Kurzay
SSSara Fresnillo Saló
Sara Fresnillo Saló
ARAnne Rahbech
Anne Rahbech
TSTina Seremet
Tina Seremet
CMCecilie Oelvang Madsen
Cecilie Oelvang Madsen
PSPer thor Straten
Per thor Straten
Cancer immunotherapy predominantly targets CD8 T cells, but recent evidence highlights the importance of CD4 T cells in adoptive cell therapy (ACT). The TAM receptor MerTK regulates immune responses and has been shown to provide costimulatory signals in CD8 T cells. However, its role in CD4 T cells remains poorly understood. Here, we demonstrate that ProS1-MerTK signaling is upregulated in activated CD4 T cells, where it enhances central memory formation, metabolic fitness, and proliferation. Mechanistically, ProS1-MerTK signaling was linked to type 1 immune responses, suggesting a regulatory role in CD4 T cell polarization. Using CRISPR-Cas9-mediated knockout, we found that loss of MerTK reduced CD4 T cell fitness, function, and polarization. Furthermore, when ProS1 was added during the expansion of tumor-infiltrating lymphocytes (TILs) from advanced melanoma biopsies, it showed potential to promote favorable CD4 T cell memory and helper phenotypes, increase stemness, and reduce exhaustion - features associated with improved responses to ACT. These findings establish ProS1-MerTK as a key pathway for modulating CD4 T cell functionality and highlight its therapeutic potential to enhance TIL-based ACT outcomes.

18 October 2024 in Journal of Leukocyte Biology
Verified
Journal Article
Open access
PDF file
ARAnne Rahbech
Anne Rahbech
AKAnnina Kurzay
Annina Kurzay
SSSara Fresnillo Saló
Sara Fresnillo Saló
TSTina Seremet
Tina Seremet
RDReno Debets
Reno Debets
PSPer thor Straten
Per thor Straten
Immune therapy using checkpoint inhibitors or adoptive cell transfer has revolutionized the treatment of several types of cancers. However, response to treatment is currently limited to a fraction of patients. Elucidation of immune modulatory mechanisms might optimize patient selection and present ways to modify anti-cancer immune responses. We recently discovered the expression and an important costimulatory role of TAM receptor MerTK signaling on activated human primary CD8+ T cells. Here we extend our study of the costimulatory role of MerTK expression in human CD8+ T cells. We uncover a clear link between MerTK expression and less differentiated Central Memory T cells based on an increased expression of CCR7, CD45RO, CD28, CD62L, and an altered metabolic profile. In addition, we observe an improved proliferative capacity and elevated expression of effector molecule IFNγ upon recall responses of MerTK-expressing cells in vitro. Finally, using gp100TCR-transduced T cells, we demonstrate how PROS1 treatment results in improved cytotoxicity and killing of tumors. Our findings describe a role of MerTK expression in T cells, which could be exploited in the search for improving immunotherapeutic approaches.

7 February 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
KLKatharina und Johannes Leuchte
Katharina und Johannes Leuchte
SSSara Fresnillo Saló
Sara Fresnillo Saló
ARAnne Rahbech
Anne Rahbech
MBMikkel Byrdal
Mikkel Byrdal
AVAnders Vinther
Anders Vinther
GOGitte Holmen Olofsson
Gitte Holmen Olofsson
Physically active individuals demonstrate enhanced immune competence. Efficient execution of effector function relies on chemokine receptor-regulated immune cell trafficking along chemokine gradients to sites of inflammation, infection, tumors, or tissue damage. This study investigates the impact of acute high-intensity interval training (HIIT) on chemokine receptor expression in leukocytes. Sixteen healthy participants completed a single HIIT session, and peripheral blood was collected before exercise (Bsl), immediately after (Ex02), and one hour later (Ex60). Surface expression of selected chemokine receptors was measured using flow cytometry on CD4+ T cells, γδ T cells, NK cells, and monocytes, followed by FlowSOM clustering. NK cells, CD4+ T cells, and γδ T cells were strongly mobilized at Ex02 and returned to or below baseline at Ex60. HIIT preferentially mobilized CX3CR1+ CXCR2+ CD56dim NK cells, CD4+ T cells expressing CX3CR1hi and CCR5+, and CX3CR1+ CD56+ γδ T cells, indicating mobilization of immune cells phenotypically associated with migratory and cytotoxic potential. Proportions of intermediate and non-classical monocytes increased at Ex02 and decreased at Ex60. In conclusion, HIIT induced a rapid redistribution of leukocyte subsets with chemokine receptor profiles suggesting enhanced endothelial interaction and migratory capacity toward effector tissues.

18 December 2024 in Biomarker Research
Verified
Journal Article
Open access
PDF file
PAPia Aehnlich
Pia Aehnlich
KLKatharina und Johannes Leuchte
Katharina und Johannes Leuchte
CSClaudia Schöllkopf
Claudia Schöllkopf
SSSara Fresnillo Saló
Sara Fresnillo Saló
TSTina J. Seremet
Tina J. Seremet
PSPer Thor Straten
Per Thor Straten
The TAM receptor tyrosine kinase family member AXL plays critical roles in tissue homeostasis, survival, chemoresistance, and motility. This study investigates the receptor expression in six AML cell lines and bone marrow myeloblasts from 25 patients with myeloid neoplasms. We found that AXL expression was generally absent or very low in AML myeloblasts. These findings suggest that the efficacy of AXL inhibitors may not depend on AXL positivity but rather on alternative therapeutic mechanisms, such as inducing significant immune responses.